# Study in Subjects With Moderate Atopic Dermatitis

> **NCT03859986** · PHASE2 · UNKNOWN · sponsor: **Ralexar Therapeutics, Inc.** · enrollment: 124 (actual)

## Conditions studied

- Atopic Dermatitis Eczema

## Interventions

- **DRUG:** ALX-101 Gel Vehicle
- **DRUG:** ALX-101 Gel 5%

## Key facts

- **NCT ID:** NCT03859986
- **Lead sponsor:** Ralexar Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-08
- **Primary completion:** 2020-01
- **Final completion:** 2020-01
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2019-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03859986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03859986, "Study in Subjects With Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03859986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*